PEG: Net loss narrowed as clinical progress and a key legal win improved financial position, but funding needs persist
Less than 1 min read
Reponex advanced clinical programs and strengthened its IP portfolio, while an arbitral award improved the outlook for recovering the Portinho S.A. receivable. The group reported a reduced net loss and improved equity, but remains pre-revenue and reliant on further financing and licensing deals.
Original document: Pharma Equity Group A/S Class A [PEG] Interim report — Aug. 14 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr